Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01214759 · ClinicalTrials.gov registry record · Phase 4
Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)
A Phase 4 study, sponsored by The University of Texas Health Science Center, Houston.
- Completed
- Registry status
- Phase 4
- Development phase
- 103
- Enrollment target
NCT01214759 is a Phase 4 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 103 participants.
The verdict
NCT01214759, a Phase 4 study, has completed, sponsored by The University of Texas Health Science Center, Houston.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 103 participants
- Enrollment target
Study Summary
This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
Interventions
- DRUG Truvada
- DRUG Raltegravir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 103 participants |
| Start Date | 2011-05 |
| Est. Completion | 2015-08 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01214759
The ClinicalTrials.gov registry entry for NCT01214759 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 103 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The University of Texas Health Science Center, Houston, which has 732 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Truvada is the first listed.
NCT01214759 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01214759 about?
NCT01214759 is a clinical study titled "Truvada Plus Raltegravir for Nonoccupational Post-exposure Prophylaxis (nPEP)". This study will evaluate the safety and tolerability of the combination of truvada and raltegravir given for 28 days for the prevention of HIV infection.
What is the current status of trial NCT01214759?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 103 participants. The study started on 2011-05. Estimated completion is 2015-08.
What interventions are being tested in trial NCT01214759?
The interventions under investigation include: Truvada (DRUG), Raltegravir (DRUG).
Who is sponsoring clinical trial NCT01214759?
This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.